MCID: VPM001
MIFTS: 52

Vipoma

Categories: Rare diseases, Endocrine diseases, Gastrointestinal diseases, Cancer diseases

Aliases & Classifications for Vipoma

MalaCards integrated aliases for Vipoma:

Name: Vipoma 12 72 49 55 51 41 14 69
Pancreatic Cholera 55 69
Pancreatic Vipoma 49 69
Malignant Vasoactive Intestinal Peptide-Secreting Tumor 12
Watery Diarrhea-Hypokalemia-Achlorhydria Syndrome 55
Vasoactive Intestinal Peptide-Secreting Tumor 12
Vasoactive Intestinal Peptide-Producing Tumor 49
Vasoactive Intestinal Peptide Tumor 49
Diarrheogenic Islet Cell Tumor 55
Verner-Morrison Syndrome 55
Vip- Secreting Tumor 12
Vip-Secreting Tumor 55
Vipoma, Malignant 12
Malignant Vipoma 69
Wdha Syndrome 55

Characteristics:

Orphanet epidemiological data:

55
vipoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



Summaries for Vipoma

NIH Rare Diseases : 49 VIPoma is a rare cancer that develops within the pancreas. This tumor causes pancreatic cells to produce high levels of a hormone called vasoactive intestinal peptide (VIP). The signs and symptoms of a VIPoma include abdominal pain, flushing or redness of the face, nausea, watery diarrhea, weight loss, dehydration, and low blood potassium (hypokalemia). VIPomas are usually diagnosed in adults around age 50. The cause of VIPoma is unknown. Treatment may include intravenous (IV) fluids to correct dehydration, medications such as octreotide to help control diarrhea, and surgery to remove the tumor. Last updated: 3/8/2010

MalaCards based summary : Vipoma, also known as pancreatic cholera, is related to pancreatic cholera and wdha syndrome, and has symptoms including neoplasm of the pancreas, hypokalemia and secretory diarrhea. An important gene associated with Vipoma is VIP (Vasoactive Intestinal Peptide), and among its related pathways/superpathways is Gastric acid production. The drugs Pancreatic Polypeptide and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and thyroid.

Wikipedia : 72 A VIPoma (also known as Verner–Morrison syndrome, after the physicians who first described it) is a rare... more...

Related Diseases for Vipoma

Diseases related to Vipoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Related Disease Score Top Affiliating Genes
1 pancreatic cholera 32.8 CALCA GAST SST VIP
2 wdha syndrome 29.9 CALCA SST VIP
3 multiple endocrine neoplasia 29.8 CALCA CHGA
4 glucagonoma 29.6 CHGA SST VIP
5 diarrhea 29.6 GAST SST
6 small cell carcinoma 29.6 CALCA CHGA
7 parathyroid adenoma 29.5 CALCA CHGA
8 hyperinsulinemic hypoglycemia, familial, 2 29.2 CHGA GAST SST
9 paraganglioma 29.2 CALCA CHGA SST
10 multiple endocrine neoplasia, type i 29.0 CHGA GAST SST VIP
11 carcinoid syndrome 28.3 CALCA CHGA NTS SST
12 neuroendocrine tumor 27.8 CALCA CHGA GAST NTS SST
13 pancreatic vasoactive intestinal peptide producing tumor 11.3
14 pancreatitis 10.4
15 secretory diarrhea 10.2 SST VIP
16 leprosy 2 10.2 CALCA VIP
17 cryptosporidiosis 10.2 SST VIP
18 vasomotor rhinitis 10.2 CALCA VIP
19 cluster headache 10.2 CALCA VIP
20 urticaria pigmentosa 10.2 CALCA VIP
21 pylorospasm 10.2 GAST SST
22 pancreatic somatostatinoma 10.2 CALCA SST
23 duodenal somatostatinoma 10.2 CALCA SST
24 postcholecystectomy syndrome 10.2 GAST SST
25 prolactin producing pituitary tumor 10.2 CALCA SST
26 retinitis pigmentosa 40 10.2 GAST SST
27 gastric neuroendocrine tumor 10.1 CALCA GAST
28 pernicious anemia 10.1 GAST SST
29 fibrous dysplasia 10.1 CALCA SST
30 adenoma of the pancreas 10.1 CHGA SST
31 stomach disease 10.1 GAST SST
32 hyperprolactinemia 10.1 SST VIP
33 pituitary carcinoma 10.1 CHGA SST
34 ganglioneuroma 10.1 CHGA VIP
35 ovarian cystic teratoma 10.1 CALCA GAST
36 carcinoid tumors, intestinal 10.1 CHGA SST
37 autoimmune atrophic gastritis 10.1 CHGA GAST
38 duodenal ulcer 10.1 GAST SST
39 atypical follicular adenoma 10.1 CALCA CHGA
40 goblet cell carcinoid 10.1 CHGA GAST
41 acute thyroiditis 10.0 CALCA CHGA
42 phaeochromocytoma 10.0 CHGA SST
43 hepatitis 10.0
44 non-functioning pancreatic endocrine tumor 10.0 CHGA GAST
45 pancreatic cystadenocarcinoma 10.0 CALCA CHGA
46 cell type benign neoplasm 10.0 CHGA SST
47 irritable bowel syndrome 10.0 CHGA VIP
48 merkel cell carcinoma 10.0 CHGA SST
49 atrophic gastritis 10.0 CHGA GAST
50 dumping syndrome 9.9 NTS SST

Graphical network of the top 20 diseases related to Vipoma:



Diseases related to Vipoma

Symptoms & Phenotypes for Vipoma

Human phenotypes related to Vipoma:

55 31 (show all 42)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neoplasm of the pancreas 55 31 hallmark (90%) Very frequent (99-80%) HP:0002894
2 hypokalemia 55 31 hallmark (90%) Very frequent (99-80%) HP:0002900
3 secretory diarrhea 55 31 hallmark (90%) Very frequent (99-80%) HP:0005208
4 diabetes mellitus 55 31 frequent (33%) Frequent (79-30%) HP:0000819
5 weight loss 55 31 frequent (33%) Frequent (79-30%) HP:0001824
6 normochromic anemia 55 31 frequent (33%) Frequent (79-30%) HP:0001895
7 dehydration 55 31 frequent (33%) Frequent (79-30%) HP:0001944
8 nausea and vomiting 55 31 frequent (33%) Frequent (79-30%) HP:0002017
9 malabsorption 55 31 frequent (33%) Frequent (79-30%) HP:0002024
10 anorexia 55 31 frequent (33%) Frequent (79-30%) HP:0002039
11 hepatomegaly 55 31 frequent (33%) Frequent (79-30%) HP:0002240
12 episodic abdominal pain 55 31 frequent (33%) Frequent (79-30%) HP:0002574
13 hypercalcemia 55 31 frequent (33%) Frequent (79-30%) HP:0003072
14 generalized muscle weakness 55 31 frequent (33%) Frequent (79-30%) HP:0003324
15 muscle cramps 55 31 frequent (33%) Frequent (79-30%) HP:0003394
16 poor appetite 55 31 frequent (33%) Frequent (79-30%) HP:0004396
17 erythema 55 31 frequent (33%) Frequent (79-30%) HP:0010783
18 chronic fatigue 55 31 frequent (33%) Frequent (79-30%) HP:0012432
19 intermittent jaundice 55 31 occasional (7.5%) Occasional (29-5%) HP:0001046
20 intrahepatic cholestasis 55 31 occasional (7.5%) Occasional (29-5%) HP:0001406
21 ascites 55 31 occasional (7.5%) Occasional (29-5%) HP:0001541
22 extrahepatic cholestasis 55 31 occasional (7.5%) Occasional (29-5%) HP:0012334
23 abnormal gastrointestinal motility 55 31 occasional (7.5%) Occasional (29-5%) HP:0030895
24 increased circulating gonadotropin level 55 31 very rare (1%) Very rare (<4-1%) HP:0000837
25 growth hormone excess 55 31 very rare (1%) Very rare (<4-1%) HP:0000845
26 prolactin excess 55 31 very rare (1%) Very rare (<4-1%) HP:0000870
27 subcutaneous lipoma 55 31 very rare (1%) Very rare (<4-1%) HP:0001031
28 respiratory insufficiency due to muscle weakness 55 31 very rare (1%) Very rare (<4-1%) HP:0002747
29 pituitary adenoma 55 31 very rare (1%) Very rare (<4-1%) HP:0002893
30 neoplasm of the liver 55 31 very rare (1%) Very rare (<4-1%) HP:0002896
31 parathyroid adenoma 55 31 very rare (1%) Very rare (<4-1%) HP:0002897
32 ganglioneuroma 55 31 very rare (1%) Very rare (<4-1%) HP:0003005
33 elevated calcitonin 55 31 very rare (1%) Very rare (<4-1%) HP:0003528
34 benign gastrointestinal tract tumors 55 31 very rare (1%) Very rare (<4-1%) HP:0006719
35 follicular thyroid carcinoma 55 31 very rare (1%) Very rare (<4-1%) HP:0006731
36 primary hyperparathyroidism 55 31 very rare (1%) Very rare (<4-1%) HP:0008200
37 adrenocortical adenoma 55 31 very rare (1%) Very rare (<4-1%) HP:0008256
38 abnormality of the abdomen 55 Occasional (29-5%)
39 abnormality of the thyroid gland 55 Very rare (<4-1%)
40 hypercortisolism 55 Very rare (<4-1%)
41 hematochezia 55 Excluded (0%)
42 increased circulating cortisol level 31 very rare (1%) HP:0003118

UMLS symptoms related to Vipoma:


diarrhea

Drugs & Therapeutics for Vipoma

Drugs for Vipoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
2 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
3
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
4
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
5
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
6
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 143 6006
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
10 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
11 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
12 Immunosuppressive Agents Phase 2, Phase 3
13 Antimetabolites Phase 2, Phase 3,Phase 1
14 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
15 Analgesics Phase 3
16 Central Nervous System Depressants Phase 3
17 Adjuvants, Anesthesia Phase 3
18 Narcotics Phase 3
19 Analgesics, Opioid Phase 3
20 Anesthetics Phase 3
21 Anesthetics, General Phase 3
22 Anesthetics, Intravenous Phase 3
23 Peripheral Nervous System Agents Phase 3
24 Folate Nutraceutical Phase 2, Phase 3
25 Vitamin B9 Nutraceutical Phase 2, Phase 3
26 Cola Nutraceutical Phase 3,Phase 2,Phase 1
27
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
28
Melphalan Approved Phase 2 148-82-3 460612 4053
29
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
30
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
31
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 6400441 383414
32
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
33
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
34
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
35
Pancrelipase Approved, Investigational Phase 2,Phase 1 53608-75-6
36
Somatostatin Approved, Investigational Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
37
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
38
Everolimus Approved Phase 2 159351-69-6 6442177
39
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
40
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
41
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354
42
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
43 Epothilone B Phase 2
44 Epothilones Phase 2
45 pancreatin Phase 2,Phase 1
46 Alkylating Agents Phase 2,Phase 1
47 topoisomerase I inhibitors Phase 2
48 Retinol palmitate Phase 2
49 Micronutrients Phase 2
50 Gastrointestinal Agents Phase 2,Phase 1

Interventional clinical trials:

(show all 22)

# Name Status NCT ID Phase Drugs
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
5 EPO906 in Carcinoid and Other Neuroendocrine Tumors Completed NCT00050349 Phase 2 EPO906 epothilone B
6 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
7 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
8 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
9 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
10 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
11 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
12 Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT01229943 Phase 2 Everolimus;Octreotide Acetate
13 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
14 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
15 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
16 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
17 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
18 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
19 Laser Tissue Welding - Distal Pancreatectomy Sealing Study Recruiting NCT03147768 Phase 1
20 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
21 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
22 Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan Enrolling by invitation NCT02102893

Search NIH Clinical Center for Vipoma

Cochrane evidence based reviews: vipoma

Genetic Tests for Vipoma

Anatomical Context for Vipoma

MalaCards organs/tissues related to Vipoma:

38
Pancreas, Liver, Thyroid, Pituitary, Endothelial, Colon, Lung

Publications for Vipoma

Articles related to Vipoma:

(show top 50) (show all 102)
# Title Authors Year
1
Percutaneous Irreversible Electroporation for Pancreatic VIPoma: A Case Report. ( 27977628 )
2017
2
Ventricular fibrillation resulting from electrolyte imbalance reveals vipoma in MEN1 syndrome. ( 27071757 )
2016
3
Emergency therapy for liver metastases from advanced VIPoma: surgery or transarterial chemoembolization? ( 27583030 )
2016
4
When Symptomatic Treatment Becomes Antitumor Treatment for Vipoma: Opportunity for Frail Elderly Adults. ( 26889855 )
2016
5
Pancreatic VIPoma visualized by 68Ga DOTA-NOC PET-CT. ( 26235641 )
2015
6
Metastatic VIPoma presenting as an ovarian mass. ( 26657531 )
2015
7
VIPoma with multiple endocrine neoplasia type 1 identified as an atypical gene mutation. ( 26564120 )
2015
8
Extra-pancreatic vipoma. ( 25184777 )
2014
9
Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma. ( 25349667 )
2014
10
Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male. ( 24785507 )
2014
11
Sunitinib Achieved Fast and Sustained Control of VIPoma Symptoms. ( 25305306 )
2014
12
VIPoma in a 37-year-old man. ( 23993192 )
2013
13
Ischemic stroke as a presenting feature of VIPoma due to MEN 1 syndrome. ( 24251163 )
2013
14
Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma). ( 23407483 )
2013
15
A rare cause of diarrhea: pancreatic VIPoma. ( 24008482 )
2013
16
VIPoma that arose from the rectum in a 65-year-old male patient. ( 22350188 )
2012
17
Diagnosis and treatment of VIPoma: a case report and literature review in China. ( 22695090 )
2012
18
Education and imaging. Hepatobiliary and pancreatic: pancreatic VIPomas associated with multiple endocrine neoplasia type I. ( 22353352 )
2012
19
MSH2 and CXCR4 involvement in malignant VIPoma. ( 23231927 )
2012
20
VIPoma Crisis: Immediate and life saving reduction of massive stool volumes on starting treatment with octreotide. ( 21509215 )
2011
21
Benign pancreatic vipoma. ( 21526882 )
2011
22
Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma. ( 20351979 )
2010
23
VIPoma syndrome: challenges in management. ( 20730389 )
2010
24
Is radiofrequency ablation justified for liver metastatic VIPoma patient undergoing Whipple procedure? ( 20819560 )
2010
25
Hypokalemic rhabdomyolysis due to watery diarrhea, hypokalemia, achlorhydria (WDHA) syndrome caused by vipoma. ( 19488018 )
2009
26
VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome. ( 19184565 )
2009
27
Nesidioblastosis as a cause of focal pancreatic 111In-pentetreotide uptake in a patient with putative VIPoma: another differential diagnosis. ( 19387771 )
2009
28
Multi-visceral resection of pancreatic VIPoma in a patient with sinistral portal hypertension. ( 18662399 )
2008
29
[Diagnostic procedures and more particularly, place of scintigraphy in neuroendocrine tumors, example of vipoma in MEN 1]. ( 17292846 )
2007
30
Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma. ( 16354964 )
2006
31
Diagnosis and treatment of VIPoma in a female patient. ( 16357627 )
2006
32
VIPomas: an update in diagnosis and management in a series of 11 patients. ( 16001675 )
2005
33
Calcitonin-secreting VIPoma. ( 16416161 )
2005
34
[Jejunal vipoma]. ( 15646540 )
2004
35
VIPoma. ( 15590967 )
2004
36
Diagnosis and treatment of VIPoma in China: (case report and 31 cases review) diagnosis and treatment of VIPoma. ( 14707737 )
2004
37
VIPoma: a rare cause of a pancreatic mass. ( 15162993 )
2004
38
Vasoactive intestinal polypeptide-secreting tumor (VIPoma) with liver metastases: dramatic and durable symptomatic benefit from hepatic artery embolization, a case report. ( 12482130 )
2002
39
Dynamic gadolinium-enhanced MR imaging of pancreatic VIPoma in a patient with Verner-Morrison syndrome. ( 11702127 )
2001
40
Vipoma: effective treatment with octreotide in the oldest old. ( 11347804 )
2001
41
Metastatic jejunal VIPoma: beneficial effect of combination therapy with interferon-alpha and 5-fluorouracil. ( 10638600 )
2000
42
Vasoactive Intestinal Peptide Tumor (VIPoma) ( 25905195 )
2000
43
VIPoma of pancreas in a child. ( 11059195 )
2000
44
Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options. ( 10389687 )
1999
45
Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. ( 10089056 )
1998
46
The cost-effectiveness of octreotide acetate in the treatment of carcinoid syndrome and VIPoma. ( 9780538 )
1998
47
Metastatic pancreatic VIPoma: deteriorating clinical course and successful treatment by liver transplantation. ( 9577908 )
1998
48
Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy. ( 9744346 )
1998
49
MR imaging of metastatic pancreatic VIPoma. ( 9408142 )
1997
50
Massive amyloid deposition in pancreatic vipoma: a case report. ( 9007963 )
1996

Variations for Vipoma

Expression for Vipoma

Search GEO for disease gene expression data for Vipoma.

Pathways for Vipoma

Pathways related to Vipoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.47 GAST VIP

GO Terms for Vipoma

Cellular components related to Vipoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.46 CALCA CHGA GAST SST
2 extracellular region GO:0005576 9.1 CALCA CHGA GAST NTS SST VIP
3 transport vesicle GO:0030133 8.96 CHGA NTS

Biological processes related to Vipoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of blood pressure GO:0008217 9.37 CALCA CHGA
2 G-protein coupled receptor signaling pathway GO:0007186 9.35 CALCA GAST NTS SST VIP
3 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.32 CALCA VIP
4 response to heat GO:0009408 9.26 CALCA SST
5 positive regulation of cAMP metabolic process GO:0030816 9.16 CALCA CHGA
6 regulation of receptor activity GO:0010469 9.02 CALCA GAST NTS SST VIP

Molecular functions related to Vipoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 8.96 NTS VIP
2 hormone activity GO:0005179 8.92 CALCA GAST SST VIP

Sources for Vipoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....